RANK-ing the Effects of Denosumab in Prostate Cancer Patients with High PSA doubling Times

Metastasis to the bone is a common feature of prostate cancers. When prostate cancers metastasize to the bone, they hijack the bone remodelling process in order to be incorporated into the newly developed bone tissue. Denosumab is a monoclonal… [Learn More…]

Diagnosis and Classification of Brain Tumors Using Mass Spectrometry

Brain tissue biopsies obtained during surgery are used to histologically diagnose and grade brain tumors, to discriminate normal from diseased tissue and to determine the best treatments. However, this approach is limited by tissue characterization… [Learn More…]

Adjunct TG4010 for Advanced Non-Small Cell Lung Cancer (NSCLC)

TG4010 (MVA-MUC1-IL2) is a poxvirus vector that has been adapted to target MUC1, which is a major tumor-associated antigen. MVA is a highly attenuated (non-pathogenic) strain, which has been tested extensively in humans as a smallpox vaccine and is… [Learn More…]

Pertuzumab: The New Kid on “HER” Block

Approximately 20% of all breast cancers are caused by the oncogenic human epidermal growth factor receptor 2 (HER2) and although trastuzumab has led to significant improvements in treating HER2-positive breast cancers, many patients develop… [Learn More…]

S-1: A Synergistic Drug Combination that Improves Overall Survival in Patients with Stage II and III Gastric Cancer

S-1 (TS-1) is a chemotherapeutic preparation combining tegafur, gimeracil and oteracil potassium in a molar ratio of 1:0.4:1 that significantly improves overall survival in patients with stage II or III gastric cancer. In this study, patients that… [Learn More…]

NovoTTF-100A Provides Non-invasive Treatment Options for Recurrent Glioblastomas

The NovoTTF-100A system is a portable, non-invasive medical device that slows and reverses tumor growth by creating low intensity, alternating electric fields within the tumor. In this study, continuous NovoTTF-100A monotherapy (20-24 hours per day,… [Learn More…]

Everolimus and Exemestane for Postmenopausal Women with Letrozole or Anastrozole-Resistant Breast Cancers

Everolimus is a drug that targets the mTOR pathway, which is over-activated in many cancers and associated with resistant to hormonal therapy in breast cancers. In this study, everolimus was used in combination with exemestane to treat… [Learn More…]

Positive Phase II Data Support Entinostat Treatment for Advanced Breast Cancer

Entinostat is an inhibitor of class I histone deacetylase, an enzyme involved in epigenetic gene regulation commonly altered in cancers. Importantly, doctors can perform a simple test to determine whether or not entinostat will be effective in a… [Learn More…]

Rindopepimut Significantly Increases Overall Survival of Treatment-Resistant Glioblastoma Patients

Rindopepimut is a vaccine that targets the epidermal growth factor receptor variant III mutation (EGFRvIII), which occurs in 31% of glioblastoma multiforme cases and is linked to poor long-term survival regardless of other factors such as extent of… [Learn More…]

New Treatment Extends Life for Men with Advanced Prostate Cancer

Most patients with advanced prostate cancer eventually become resistant to anti-androgen therapy (including bicalutamide therapy). MDV3100 is an advanced drug that blocks multiple processes of androgen signalling including binding of testosterone to… [Learn More…]